Stock listing
NASDAQ:RGLS Regulus Therapeutics Inc Stock
Follow Regulus Therapeutics Inc into a list and get an email when it puts out news.
Last close · NASDAQ:RGLS
$8.16 USD
Close on Jun 24, 2025 · No longer trades
- Lowest – highest close
- $0.793 – $8.30 USDSince Jun 29, 2022 · lowest Mar 27, 2023 · highest Jun 9, 2025
Delisted NASDAQ:RGLS no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:RGLS
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
Regulus Therapeutics Inc on 6ix
- Calls
- 7 calls with a replay · 7 with a transcript · latest Nov 10, 2022
- Decks
- 4 decks · latest Mar 27, 2025
Events
| Call | When | Status |
|---|---|---|
| Regulus Therapeutics (RGLS) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 5:00 PM ET | Replay |
| Regulus Therapeutics (RGLS) Q2 2022 Earnings Call | Thu, Aug 11, 2022 · 5:00 PM ET | Replay |
| Regulus Therapeutics (RGLS) Q1 2022 Earnings Call | Thu, May 12, 2022 · 5:00 PM ET | Replay |
| Regulus Therapeutics (RGLS) Q4 2021 Earnings Call | Thu, Mar 10, 2022 · 5:00 PM ET | Replay |
| Regulus Therapeutics (RGLS) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 5:00 PM ET | Replay |
| Regulus Therapeutics (RGLS) Q2 2021 Earnings Call | Tue, Aug 10, 2021 · 5:00 PM ET | Replay |
| Regulus Therapeutics (RGLS) Q1 2021 Earnings Call | Thu, May 13, 2021 · 5:00 PM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (March 2025) | Technical | 10 slides | Mar 27, 2025 |
| Investor Presentation (October 2021) | Investor deck | 36 slides | Oct 18, 2021 |
| Rare & Orphan Disease Summit (May 2021) | Conference | 30 slides | May 21, 2021 |
| Investor Presentation (December 2020) | Investor deck | 43 slides | Dec 1, 2020 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Garry E. Menzel Other companies: Adaptimmune Therapeutics PLC (Non-Executive Director · Since at least Jun 1, 2023); Stoke Therapeutics, Inc. (Director · Since at least Aug 13, 2020); Black Diamond Therapeutics, Inc. (Operating Partner, GHO Capital Partners LLP · Since at least Jan 29, 2020); Tcr2 Therapeutics Inc (President and CEO, Director · Feb 13, 2019 – Jun 1, 2023 · Past); DaVita Inc. (Senior Vice President, Finance · Sep 9, 2013 – Sep 9, 2013 · Past) | COO & Executive VP, Finance · Oct 4, 2012 – Dec 11, 2012 · Past |
| Stelios Papadopoulos Other companies: Ovid Therapeutics Inc. (Director, Member of the Audit and Compensation Committees · Since at least Mar 1, 2025); Exelixis, Inc. (Chair of the Board, Exelixis, Inc. · Since at least May 24, 2012); BG Medicine Inc (Director · Since at least Nov 9, 2011); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Nov 24, 2020 · Past); Biogen Inc. (Director · Jun 8, 2012 – Jun 15, 2022 · Past) | Director · Since at least Oct 4, 2012 |
| Mark Foletta Other companies: Enanta Pharmaceuticals, Inc. (Director · Since at least Jun 29, 2020); AMN Healthcare Services Inc (Director · Since at least Nov 27, 2017); DexCom, Inc. (Director · Since at least Nov 27, 2017); Tocagen Inc (EVP & Chief Financial Officer · Dec 8, 2017 – Oct 4, 2019 · Past) | Director · Dec 4, 2017 – Dec 4, 2017 · Past |
| Jason Raleigh Nunn Other companies: Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Trevena, Inc. (Director · May 16, 2019 – Jun 13, 2024 · Past) | Director · Since at least Jun 6, 2019 |
| Neil Gibson Other companies: Instil Bio, Inc. (Board Member · Since at least Mar 18, 2021); Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Jun 1, 2023 · Past) | Chief Scientific Officer · Oct 4, 2012 – Jan 28, 2015 · Past |
| Pascale Witz Other companies: Revvity, Inc. (Director · Since at least Oct 27, 2017); Tesaro Inc (Director · May 10, 2018 – Jan 22, 2019 · Past); Horizon Pharma PLC (Director · Aug 2, 2017 – Aug 2, 2018 · Past) | Director · Since at least Jun 1, 2017 |
| Daniel R Chevallard Other companies: LENZ Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 21, 2024); Viracta Therapeutics Inc (CFO and COO · Mar 26, 2021 – Mar 12, 2024 · Past) | Chief Financial Officer · May 4, 2017 – Jul 1, 2019 · Past |
| David Baltimore Other companies: Amgen Inc. (Director · Mar 30, 2016 – Apr 27, 2018 · Past); Immune Design Corp (Director · Jan 4, 2016 – Apr 2, 2019 · Past) | Director · Since at least Jun 2, 2016 |
| Simos Simeonidis Other companies: Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past) | Director · Jun 6, 2019 – Jun 9, 2022 · Past |
| Timothy Michael Wright Other companies: Schrodinger, Inc. (Director · Feb 5, 2020 – Feb 10, 2020 · Past) | Chief R & D Officer · Dec 4, 2017 – Feb 5, 2019 · Past |
All 14 people
| Person | Seat |
|---|---|
| Alice Shih-hou Huang | Director · Since at least Jan 6, 2021 |
| Christopher Ray Aker | Sr. VP & General Counsel · Since at least Jan 1, 2019 |
| Denis Drygin | Chief Scientific Officer · Aug 3, 2020 – Mar 1, 2022 · Past |
| Hugh Rosen | Director · Since at least Jun 2, 2016 |
Log in to ask 6ix AI your own questions about Regulus Therapeutics Inc.